Maersk has been providing global pharmaceutical players in Central Europe professional warehousing and distribution services since 2001, specifically tailored to meet the needs of this demanding customer segment. Building further on its experience and to address growing customer needs, Maersk launched a project in late 2020 to create a second pharmaceutical warehouse as part of its existing warehousing and distribution centre in Mszczonów near Warsaw in Poland, which has now been officially inaugurated and is made available to customers.The new warehouse, the first one in Poland with BREEAM Excellent certificate, is fully dedicated to pharmaceutical customers and is located on a plot fully owned by Maersk. The building has photovoltaic panels installed on the roof, as well as a chilled water system used to supply power to the coolers of all air handling units and fan coils. In addition, the heat recovery installation will supply the buffer tank located in the gas boiler room and recycled heat collected in that way will be used to supply heaters in air handling units during the summer. The facility will have integrated Quality Management System implemented, based on Good Distribution and Manufacturing Practice and ISO certificates.Cold storage is one of the key services Maersk offers to its pharma customers. Today, the global Maersk Pharma team handles over 25,000 orders per year for more than 30 key clients transporting pharmaceutical and veterinary products, medical devices, and dangerous Pharmaceutical goods.Available space: 15 000 sqm;Operational height: 11,5 m;Approximate capacity: 24 000 pallet places40 km from Warsaw Chopin AirportNext to S7 motorway, connecting two most populous Polish metropolitan areas – Silesia and Mazovia with WarsawEasy access to A1 and A2 – two major Polish highways, linking North with South and East with WestThe pharmaceutical industry is becoming increasingly focused on sustainability across its production and supply chain, in line with the EU’s Pharmaceutical Strategy for Europe, which paves a way for the industry to contribute to EU’s climate neutrality, with a focus on reducing greenhouse emissions along the value chain.
Maersk has been providing global pharmaceutical players in Central Europe professional warehousing and distribution services since 2001, specifically tailored to meet the needs of this demanding customer segment. Building further on its experience and to address growing customer needs, Maersk launched a project in late 2020 to create a second pharmaceutical warehouse as part of its existing warehousing and distribution centre in Mszczonów near Warsaw in Poland, which has now been officially inaugurated and is made available to customers.The new warehouse, the first one in Poland with BREEAM Excellent certificate, is fully dedicated to pharmaceutical customers and is located on a plot fully owned by Maersk. The building has photovoltaic panels installed on the roof, as well as a chilled water system used to supply power to the coolers of all air handling units and fan coils. In addition, the heat recovery installation will supply the buffer tank located in the gas boiler room and recycled heat collected in that way will be used to supply heaters in air handling units during the summer. The facility will have integrated Quality Management System implemented, based on Good Distribution and Manufacturing Practice and ISO certificates.Cold storage is one of the key services Maersk offers to its pharma customers. Today, the global Maersk Pharma team handles over 25,000 orders per year for more than 30 key clients transporting pharmaceutical and veterinary products, medical devices, and dangerous Pharmaceutical goods.Available space: 15 000 sqm;Operational height: 11,5 m;Approximate capacity: 24 000 pallet places40 km from Warsaw Chopin AirportNext to S7 motorway, connecting two most populous Polish metropolitan areas – Silesia and Mazovia with WarsawEasy access to A1 and A2 – two major Polish highways, linking North with South and East with WestThe pharmaceutical industry is becoming increasingly focused on sustainability across its production and supply chain, in line with the EU’s Pharmaceutical Strategy for Europe, which paves a way for the industry to contribute to EU’s climate neutrality, with a focus on reducing greenhouse emissions along the value chain.
